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The Current Role of Prostatic Acid Phosphatase and ProstateSpecific Antigen in the Management of Prostate Cancer

Sugandh D. Shetty, MD,* and Joseph C. Cerny, MD*

C

ancer of the prostate (CAP) is the most common cancer in
the American male with 132,000 new cases expected to be
diagnosed in 1992 (1). It is also the second leading cause of cancer-related deaths with 34,000 men projected to die this year (1).
Early diagnosis depends upon the availability of a sensitive and
specific tumor marker. Prostatic acid phosphatase (PAP) has
been used for staging and monitoring CAP for the last 50 years
(2). Recently, with the development of prostate-specific antigen
(PSA), interest in PAP has diminished considerably.

Prostatic Acid Phosphatase
PAP is a sialoglycoprotein, molecular weight 100,000 daltons, secreted by the prostatic acinar cells (2). Ultrastructurally
it is present in the lysosomes, secretory vacuoles, and golgi bodies (3). PAP is secreted into the acinar and the ductal lumen and
is present in high concentration in the ejaculate. Due to the large
size ofthe PAP molecule, serum levels rise only after cancer has
penetrated the prostate capsule Since its isolation in 1938 by
Gutman and Gutman (4) and the demonstration of its respon.se
to endocrine manipulation of prostate cancer by Huggins and
Hodges (5), acid phosphatase has been extensively studied regarding its usefulness for early diagnosis, staging, and monitoring CAP (2,6-12). However, because similar isoenzymes are
present in virtually every tissue in the body, the nonspecificity
ofthe PAP test has limited its diagnostic value. Even though radioimmunoassays are more sensitive than the former enzymatic
assays, PAP values cannot be used reliably in screening (13). In
addition to diurnal and individual variation, PAP levels rise after digital rectal examination (DRE), prostatic massage, cystoscopy, or transurethral resection of the prostate (2,14,15).
Although testing for PAP has declined because of the availability of PSA, such tests were the best available means to monitor patients with CAP for nearly five decades. Several studies
have shown that in pathologically confirmed stage A and B disease (Table 1) PAP is in the normal range and patients with localized disease who had elevated PAP levels later developed
bony metastasis (6-10). Thus, raised PAP levels can be used to
predict extracapsular penetration even though 20% of patients
with skeletal metastasis have normal values (2). tn assessing
whether normal PAP predicts extracapsular extension, Bahnson
and Catalona (11) studied 102 patients with surgically staged.
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clinically localized CAP and found that 22 (88%) of 25 patients
whose PAP (enzymatic assay) was in the upper half of the normal range had stage C or D disease. By comparison, only 53% of
77 patients with lower range of normal PAP had stage C or D
disease. Similarly, Oesterling et at (12) reported that the rate of
capsular penetration and seminal vesicle involvement was 11%
and 0%, respectively, in patients whose PAP level was in the
lower range of normal, compared to 50% capsular penetration
and seminal vesicle involvement for patients in the upper normal range. In addition, PAP has been used to predict skeletal
metastasis in patients being followed after radical prostatectomy, radiotherapy, and hormonal manipulation (2,13).
Cunentiy the role of PAP is limited to initial detection of extraprostatic extension of the adenocarcinoma where imaging
studies such as transrectal ultrasonography (TRUS) or computed tomography have been equivocal. PAP can also be used in
monitoring patients with stage C and D adenocarcinoma who
are on either radiotherapy or hormonal therapy.

Prostate-Specific Antigen
PSA, a glycoprotein of the serine protease group similar to
kaltikrein, has a molecular weight of 33,000 daltons and is a
much smaller molecule than PAP (16). Produced by the prostatic acinar epithelium, PSA has been located ultrastructurally in
the rough endoplasmic reticulum and is stored in vesicles and
vacuoles (3). PSA production is thought to be androgen-dependent (17-19). Physiologically, PSA liquifies the semen, degrading the seminal vesicular proteins. In 1971 Hara et at (20)
first isolated the protein from human semen and called it gamma
seminoprotein. Wang and coworkers (16) extracted the protein
from human prostate and termed it prostate-specific antigen. In
1980 Papsidero et al (21) isolated the same antigen from the semm of prostate cancer patients. Since then, many studies have
shown its assay to be useful in diagnosis, screening, staging, and
monitoring of prostate cancer (22-28). Several studies have con-

Submitted for publication; January 27. 1992.
Accepted for publication; February 24, 1992.
*Department of Urology, Henry Ford Hospital.
Address correspondence to Dr. Cemy, Department of Urology, Henry Ford Hospital.
2799 W Grand Blvd. Detroit, MI 48202.

Role of PAP and PSA in Prostate Cancer—Shetty & Cemy

93

Table 1
Clinical Staging of Prostate Cancer
Stage

Table 2
BPH and Incidence of Raised PSA > 10 ng/mL

Definition

Number of Patients with Raised
PSA> 10 ng/mL

Reference
A
A1
A2
B1
B2
B3
C
DI
D2

Incidental cancer
< 5% of tissue (Gleason < 4)
> 5% of tissue (Gleason > 4)
Palpable nodule extending into < 50% of one lobe
Palpable nodule larger than B1, limited to one lobe
Bilateral palpable cancer
Palpable cancer extending into one or both seminal vesicles
Positive pelvic lymph nodes
Skeletal or vi,sceral metastasis

firmed the identity of PSA and gamma seminoprotein (17,29).
There are two assays currentiy available for PSA. The radiometric monoclonal antibody assay (Tandem-R, Hybritech) is the
most widely used and has a normal range of 0.2 to 4.0 ng/mL
(22,23,25-30). The polyclonal assay (Proscheck) developed by
Yang (31) is also used by some investigators (15,24,32-36) and
the normal range varies from 0.2 to 2.6 ng/mL.

Hudson etal (28)
Myrtle et al (37)
Ercole et al (38)
Oesterling et al (39)
Cooner et al (40)
Henry Ford Hospital (unpublished data)

3 of 168 (2%)
7 of 352 (2%)
10 of 357 (3%)
7 of 72 (10%)
8 of 197 (4%)
14 of 124 (11 %)

lizing TRUS and PSA, we found a linear relationship between
gland volume and PSA (unpublished data).
While BPH does clearly elevate semm PSA, clinical application of this correlation must be judiciously employed. While
there seems to be a volume-dependent linear correlation between PSA and BPH tissue, levels above 10 ng/mL are infrequent in BPH, Therefore, PIN and occult CAP must also be considered as contributing factors for elevated PSA in patients with
presumed BPH.

PSA and Benign Prostatic Hyperplasia
The increase in glandular size characteristic of benign prostatic hyperplasia (BPH) results in increased PSA production by
the prostatic epithelium, Armitage et al (22) studied 139 patients
with clinical BPH using the Tandem-R assay. Of the 121 patients with histologic diagnosis of BPH, the mean PSA was 5.9
ng/mL, while in the 18 who were found to have latent cancer
(stage A) mean PSA was 18.3 ng/mL. PSA levels were higher in
men with larger prostate glands and those who presented with
acute urinary retention had a mean PSA of 11.5 ng/mL, compared to 3.8 ng/mL in those whose symptoms were only of
prostatism, independent of the glandular size Morote et al (25)
reported PSA levels > 10 ng/mL in more than 50% of BPH patients with acute urinary retention and indwelling catheters.
Hudson et al (28) reported that only 21% of men with BPH have
etevated PSA (> 4 ng/mL) and only 2% have PSA > 10 ng/mL.
Table 2 shows the incidence of PSA > 10 ng/mL (Tandem-R)
in several studies of BPH (28,37-40). Yang (31), using the
Proscheck assay, found 62% of men with BPH to have PSA >
2.5 ng/mL, and Stamey et al (15), using the same assay, found
86% of 73 BPH patients to have elevated PSA (mean 7.9 ng/
mL). Observing the rate of fall of PSA after prostatectomy and
relating it to the mass of resected adenomatous tissue, Stamey et
al (15) concluded that BPH tissue elevates semm PSA level by
0.3 ng/mL/g. However, Weber et al (18) could not demonstrate
such a consistent conelation between serum PSA and the BPH
tissue, probably because of the variable epithelial content in the
hyperplastic glands. Prostatic intraepithelial neoplasia (PIN)
has been shown to be responsible for the raised PSA in some
BPH patients (41,42). Utilizing TRUS, Babaian et al (43) estimated prostate gland volume in 408 men and found a statistically significant conelation of PSA with prostate volume and to
a lesser degree with patient age. In our study of 124 patients uti-
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Effect of Prostate Manipulation on PSA
Yuan and Catalona (44) studied the relationship of PSA,
DRE, prostatic massage TRUS, and needle biopsy. DRE had no
influence on 5- and 90-minute post-DRE PSA levels. Only 5%
of patients had elevated PSA after massage and 8% after TRUS,
but PSA was elevated in 89% after needle biopsy (5 minutes)
and in a third of those it remained high even after two weeks.
The postbiopsy rise in PSA occuned following multiple biopsies (more than four). Prostatic size, baseline PSA, and the presence of prostate cancer had no influence on persistence of raised
PSA. However, using the Proscheck assay, Stamey et at (15)
demonstrated a significant rise in PSA and PAP foltowing prostate massage, cystoscopy, and biopsy. Inflammatory conditions
of the prostate gland such as acute prostatitis also cause elevated
PSA (29).

PSA and Carcinoma of Prostate
Since PAP was the standard tumor marker for CAP before
PSA was available, earlier studies compared its efficacy to that
of PAP. Stamey et al (15) compared PSA and PAP levels in 127
untreated patients with CAP. PSA was raised above 2.5 ng/mL
(Proscheck) in 122 (96%) patients, including 7 of 12 patients
with stage A and all 115 patients with stages B to D. However,
PAP was raised in only 57% of the patients; none with stage A,
9% with B1,39% with B2,40% with B3,64% with C, and 96%
with D2. Myrtle et al (37), who studied 553 CAP patients using
Tandem-R assay, found raised PSA in 81% while only 43% had
raised PAP. The increased sensitivity is present in early disease.
For all stages of prostate cancer, PSA is elevated more frequently than PAP, probably because its small molecular size
readily permits diffusion across the basement membrane into
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Table 3
PSA Values for BPH and Organ-Confined CAP*
Percentage of Patients with PSA in the Range of
Total Patients

< 4 ng/mL

4-10 ng/mL

> 10 ng/mL

Reference

BPH

CAP

BPH

CAP

BPH

CAP

BPH

Hudson et al (28)
Lange et al (30)
Partin et al (45)

168
357
72

ll).5

79

38

31
185

47

4.S

19
IS
46

26
32
44

2
3
7

36
23
11

597

310

75

43

22

37

3

20

CAP

*.Adapted from Oesterling JE. Prostate specific antigen; A critical assessment of the most useful marker for adenocarcinoma of the
prostate. J Urol 1991:145:907-23.

the circulation. Stamey et al (24,32) showed a linear relationship
of PSA between cancer volume and Gleason score. However, a
consistent relationship between the PSA and poorly differentiated tumors could not be confirmed by Partin et al (45). Stamey
et al (32) evaluated changes in PSA values after radical prostatectomy. Given PSA half-life (2.5 to 3 days), they concluded
that cancerous tissue raises serum PSA by 3 ng/mL/g.

Role of PSA in Screening
Since PSA is an improved marker for CAP, interest in its possible role in screening is considerable. As previousty noted, the
minimal elevations of PSA which are found in BPH patients
cau.se difficulty. In an exhaustive review, Oesterling (29) compared PSA values of patients with BPH to those of patients with
localized (organ-confined) CAP (Tabte 3). As many as 43% of
CAP patients had normal PSA (< 4 ng/mL) while 25% of patients with BPH had PSA > 4 ng/mL. tn patients with organ-confined CAP, PSA > 4 ng/mL had a 64% diagnostic accuracy and
PSA > to ng/mL had a 70% diagnostic accuracy. The positive
predictive value (PPV) was 49% and 75% for PSA > 4 ng/mL
and > 10 ng/mL, respectively. Thus, due to overlap with both
BPH and inflammatory prostatic disease, PSA is not specific
enough to be used alone for screening.
Several investigators (26,27,33,46) have studied the use of
PSA in conjunction with DRE and TRUS in early detection of
CAP. Cooner et al (27) reported on 1,807 symptomatic patients
seen in a urologic clinic. All were evaluated using PSA, DRE,
and TRUS. Patients with hypoechoic lesions shown by TRUS
had biopsies. When both DRE and TRUS were negative, biopsies were not performed regardless of the PSA level. When PSA
was > 10 ng/mL in the presence of abnormal DRE, PPV approached 80%. For PSA level of 4 ng/mL with abnormal DRE,
PPV fell to 45%. For PSA > 10 ng/mL with negative DRE, the
PPV fell to 31 % (Table 4). Catalona et al (26) measured PSA in
1,653 healthy men over 50 years of age, a tme screening study.
Those who had PSA > 4 ng/mL had DRE and TRUS. Biopsies
were performed for abnormal DRE and/or TRUS. Only 107
(6%) had PSA of 4.0 to 9.9 ng/mL and 30 (2%) had PSA > 10
ng/mL. Only 22% of those with PSA < 10 ng/mL who had biopsy were shown to have CAP whereas 67% of those with PSA
> to ng/mL had CAP. Twelve (32%) and 16 (43%) ofthese pa-
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tients with CAP had normal DRE and TRUS, respectively, and
would have been missed if these modalities were utilized alone.
Multivariate analysis of PSA as the predictor of cancer (compared to Oiat of age, DRE, and TRUS) disclosed that PSA had
significant predictive ability. Lee et al (46) examined 256 men
who had hypoechoic lesions demonstrated by TRUS, 106
(41%) of whom had CAP. Positive DRE and raised PSA (> 2.6
ng/mL, Proscheck) in these patients had a PPV of 71 % for CAP
(Table 5) (33). Raised PSA had greater diagnostic significance
than positive DRE. However, Brawer and Lang (47) noted a
32% false-negative rate (PSA < 4 ng/mL) and 58% of the cancers would have been missed if 10 ng/mL had been cho.sen as the
cutoff level. In 54 unsetected CAP patients studied at Henry
Ford Hospital, 22%. had PSA < 4 ng/mL and would therefore
have been misdiagno.sed by the test. Due to the poor specificity
of PSA, several other parameters have been suggested to aid
early detection of CAP. Prostate-specific antigen density
(PSAD), defined as the ratio of PSA over prostate volume, has
been suggested (48,49). We analyzed 335 patients who underwent TRUS for suspicious DRE or an elevated PSA (> 4 ng/mL)
and found that a PSAD of 0.12 had the best efficacy values (sensitivity, specificity, positive and negative predictive value) for
the PSA range of 4 to 10 ng/mL (unpublished data. Table 6).
PSAD > 0.15 has been suggested by other investigators (50).
Another suggested parameter for early detection of CAP is rising PSA level. Stamey (34) recommends annual PSA testing in
those with borderline levels, for rising PSA titers should alert
the physician to a malignant process in the prostate.
Although PSA is raised in many patients with localized CAP,
its use in screening cannot be justified because of its high falsenegative rate, as well as the poor PPV for patients with lower
range elevations. However, a combination of PSA and DRE
with or without TRUS improves the detection rate of CAP.

PSA in Staging
Despite a linear conelation between PSA and pathological
stage the use of PSA for preoperative staging is limited by the
overlap of levels between stages. PSA levels of > 10 ng/mL
were found in 11 % to 23% of patients with organ-confined CAP
(29,45). However, using the Proscheck assay, Stamey et al (32)
reported that patients with PSA < 10 ng/mL have little chance
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Table 4
Positive Predictive Value of DRE and PSA*

Table 5
Positive Predictive Value for a Hypoechoic
Lesion on TRUS*

Digital Rectal Examination
PSA
< 4 ng/mL
4 to 10 ng/mL
> 10 ng/mL

+
16.9%
45%
76.7%

-

Digital Rectal Examination

9.3%
20%
30.9%

*Adapted from Cooner WH, Mosely BR, Rutherford CL Jr, et al. Clinical application of
transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J
Urol 1988;139:758-61.
-I- = Abnormal on DRE (nodule, induration, asymmetry).
— = Prostate with normal consistency.

for seminal vesicle and lymph node involvement. On the other
hand, patients with PSA > 50 ng/mL canied a 90% chance of
lymph node involvement. Oesterling et al (39) found that the
false-positive rate of PSA as predictor of extracapsular penetration was 74% and 65% for a cutoff level of 4 and 10 ng/mL, respectively. The ratio of polyclonal to monoclonal assay values
in the same patient has been reported to predict lymph node involvement (51). The ability of PSA to predict skeletal metastasis
has been studied by Chybowski et al (52) who found that PSA <
20 ng/mL had a negative predictive value of 99,7%. Similarly,
the negative accuracy of PSA < 20 ng/mL was 92%. These results suggest that the expensive isotope bone scan may be unnecessary in CAP patients with PSA < 20 ng/mL.

PSA in Monitoring CAP
Considering the half-life of PSA (2.5 to 3 days), semm levels
should be undetectable three weeks after radical prostatectomy
(29,30). Persistentiy raised PSA after this period suggests residual benign or malignant prostatic tissue Stamey et al (32)
showed that 95% of patients with elevated PSA three to six
months after radical prostatectomy had positive margins, seminal vesicle involvement, or lymph node disease. Lange et al (30)
performed anastomotic biopsy on patients with raised PSA three
to six months after surgery. Although none had detectable residual or recunent disease, 39% were shown to have biopsy-posi-

PSA (Proscheck)

+

-

> 2.6 ng/mL
0.2 to 2.6 ng/mL

71 '/<
26%

34%
5%

•Adapted from l^e F, Torp-Pedersen ST. Littrup PJ. et al. Hypoechoic lesions of the
prostate: Clinical relevance of tumor size, digilal rectal examination, and prostate-specific
antigen. Radiology 1989:170:29-32.

tive local disease. Local adjuvant radiotherapy has been advocated for those with raised PSA after radical prostatectomy.
Stamey et al (35), studying 183 patients who received radiotherapy for localized disease, observed that only 11 % had undetectable PSA at a mean of 5 years posttreatment. Most of the patients (82%) showed a rapid fall of PSA during the first year, but
in only 8% did the fall continue beyond one year. Rising PSA
tevels, seen in 51 % of the 80 patients followed for more than one
year, conelated with the development of skeletal metastasis and
positive prostate biopsy. However, patients who develop D2
disease foltowing radiotherapy for local disease have much
lower PSA levels than do those with unti-eated D2 disease (35).
The response of PSA to antiandrogen therapy is more dramatic than that to radiotherapy. Stamey et al (36) suggest that
the PSA level six months after beginning hormonal therapy is
prognostic of whether the patient would respond favorably to
the treatment. In addition to the antitumor effect of hormonal
therapy, androgen-dependent PSA deregulation may be responsible for the rapid fall. Rising PSA in patients with CAP suggests progression and the need for further therapy.

Summary
Although PSA is considered to be the true serum marker of
prostatictissueand a valuable indicator for cancer in the gland,
knowledge of its significance and limitations is essential to its
use for screening, staging, and monitoring CAP. PSA may be

Table 6
Efficacy of Various PSAD Values in DiiTerentiating
BPH and CAP in PSA Range of 4 to 9.9 ng/mL
PSAD Values
0.08
Sensitivity
Specificity
Positive predictive value
Negative predictive value

97%
28%
27%
97%

0.10
9(1''/;
48%
32%
95%

0.12

0.15

0.2

87%
60%
37%
94%

70%
71%
40%
90%

53%
86%
50%
87%

Sensitivity: True positive (TP)A'P + fal.se-negative (FN).
Specificity: True negative (TN)/TN false-positive (FP).
Positive predictive value: TP/TP + FP.
Negative predictive value: TN/TN -i- FN.
Diagnostic accuracy: TP + TNATP -i- TN -i- FP -(- FN.
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used in conjunction with DRE for eariy detection of CAP. Men
with abnormal DRE should have a TRUS with or without biopsy. In men older than 50 years and with negative DRE and
PSA < 4 ng/mL, annual evaluations are prudent. In patients with
a PSA range of 4.0 to 9.9 ng/mL, high-risk groups such as black
males and those with a positive family history should have
TRUS. Males with negative DRE in the PSA range of 4.0 to 9.9
ng/mL should have TRUS to evaluate prostate volume and
PSAD. Biopsy should be considered in those with PSAD > 0.15.
Men with PSA > 10 ng/mL, even in the presence ofan enlarged
benign prostate, should have multiple directed biopsies under
TRUS guidance.
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